Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 374

1.

Sick Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention Updated.

Sniderman AD, Thanassoulis G, Wilkins JT, Furberg CD, Pencina M.

J Am Heart Assoc. 2018 Oct 2;7(19):e010049. doi: 10.1161/JAHA.118.010049. No abstract available.

2.

Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

Dhruva SS, Huang C, Spatz ES, Coppi AC, Warner F, Li SX, Lin H, Xu X, Furberg CD, Davis BR, Pressel SL, Coifman RR, Krumholz HM.

Hypertension. 2017 Jul;70(1):94-102. doi: 10.1161/HYPERTENSIONAHA.117.09221. Epub 2017 May 30.

PMID:
28559399
3.

Diabetes and Cognitive Decline in Older Adults: The Ginkgo Evaluation of Memory Study.

Palta P, Carlson MC, Crum RM, Colantuoni E, Sharrett AR, Yasar S, Nahin RL, DeKosky ST, Snitz B, Lopez O, Williamson JD, Furberg CD, Rapp SR, Golden SH.

J Gerontol A Biol Sci Med Sci. 2017 Dec 12;73(1):123-130. doi: 10.1093/gerona/glx076.

PMID:
28510619
4.

Unsuccessfully Treated Hypertension: A Major Public Health Problem With a Potential Solution.

Furberg CD, Sealey JE, Blumenfeld JD.

Am J Hypertens. 2017 Sep 1;30(9):857-860. doi: 10.1093/ajh/hpx068.

PMID:
28482060
5.

The Harms of Antipsychotic Drugs: Evidence from Key Studies.

Moore TJ, Furberg CD.

Drug Saf. 2017 Jan;40(1):3-14. doi: 10.1007/s40264-016-0475-0.

PMID:
27864791
6.

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol.

Sniderman AD, Islam S, McQueen M, Pencina M, Furberg CD, Thanassoulis G, Yusuf S.

J Am Heart Assoc. 2016 Oct 13;5(10). pii: e003665.

7.

An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB.

Sniderman AD, Toth PP, Thanassoulis G, Furberg CD.

J Clin Lipidol. 2016 Sep-Oct;10(5):1248-58. doi: 10.1016/j.jacl.2016.07.008. Epub 2016 Aug 2.

PMID:
27678443
8.

Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014.

Moore TJ, Furberg CD, Mattison DR, Cohen MR.

Pharmacoepidemiol Drug Saf. 2016 Jun;25(6):713-8. doi: 10.1002/pds.3979. Epub 2016 Feb 10.

PMID:
26861066
9.

Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study.

Garg PK, Arnold AM, Hinckley Stukovsky KD, Koro C, Jenny NS, Mukamal KJ, Criqui MH, Furberg CD, Newman AB, Cushman M.

Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):750-6. doi: 10.1161/ATVBAHA.115.306647. Epub 2016 Feb 4.

10.

Electronic Health Data for Postmarket Surveillance: A Vision Not Realized.

Moore TJ, Furberg CD.

Drug Saf. 2015 Jul;38(7):601-10. doi: 10.1007/s40264-015-0305-9. Review.

PMID:
26025018
11.

Is the Guideline Process Replicable and, if Not, What Does This Mean?

Sniderman A, Furberg CD, Toth PP, Thanassoulis G.

Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):3-9. doi: 10.1016/j.pcad.2015.05.002. Epub 2015 May 7. Review.

PMID:
25958015
12.

Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C.

Pencina MJ, D'Agostino RB, Zdrojewski T, Williams K, Thanassoulis G, Furberg CD, Peterson ED, Vasan RS, Sniderman AD.

Eur J Prev Cardiol. 2015 Oct;22(10):1321-7. doi: 10.1177/2047487315569411. Epub 2015 Jan 29.

PMID:
25633587
13.

The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease.

Toth PP, Thanassoulis G, Williams K, Furberg CD, Sniderman A.

J Clin Lipidol. 2014 Nov-Dec;8(6):594-605. doi: 10.1016/j.jacl.2014.08.004. Epub 2014 Aug 30.

PMID:
25499942
14.

Plasma renin testing to guide antihypertensive therapy.

Viera AJ, Furberg CD.

Curr Hypertens Rep. 2015 Jan;17(1):506. doi: 10.1007/s11906-014-0506-0. Review.

PMID:
25432898
15.

Linked publications from a single trial: a thread of evidence.

Altman DG, Furberg CD, Grimshaw JM, Shanahan DR.

Trials. 2014 Sep 23;15:369. doi: 10.1186/1745-6215-15-369. No abstract available.

16.

JNC 8: shortcomings in process and treatment recommendations.

Furberg CD, Alderman MH.

Am J Hypertens. 2014 Dec;27(12):1443-5. doi: 10.1093/ajh/hpu158. Epub 2014 Sep 5. No abstract available.

PMID:
25194154
17.

Introduction. Tribute to John Laragh, MD - clinician and scientific researcher.

Furberg CD.

Am J Hypertens. 2014 Aug;27(8):995. doi: 10.1093/ajh/hpu139. No abstract available.

PMID:
25103926
18.

Taking a longer term view of cardiovascular risk: the causal exposure paradigm.

Sniderman AD, Toth PP, Thanassoulis G, Pencina MJ, Furberg CD.

BMJ. 2014 May 21;348:g3047. doi: 10.1136/bmj.g3047. No abstract available.

PMID:
24850828
19.

A pilot test of a new tool for remote blood pressure monitoring.

Boman K, Brenander A, Gustavsson M, Furberg CD.

J Telemed Telecare. 2014 Jul;20(5):239-241. Epub 2014 May 15.

PMID:
24833661
20.

Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials.

Thanassoulis G, Williams K, Ye K, Brook R, Couture P, Lawler PR, de Graaf J, Furberg CD, Sniderman A.

J Am Heart Assoc. 2014 Apr 14;3(2):e000759. doi: 10.1161/JAHA.113.000759.

21.

Republished: pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications.

Singh S, Loke YK, Enright P, Furberg CD.

Postgrad Med J. 2014 Apr;90(1062):205-7. doi: 10.1136/postgradmedj-2011-201275rep.

PMID:
24643260
22.

Tiotropium and the risk of death in COPD.

Loke YK, Singh S, Furberg CD.

N Engl J Med. 2014 Jan 30;370(5):480-1. doi: 10.1056/NEJMc1314411. No abstract available.

PMID:
24476442
23.

Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.

Phillips W, Piller LB, Williamson JD, Whittle J, Jafri SZ, Ford CE, Einhorn PT, Oparil S, Furberg CD, Grimm RH Jr, Alderman MH, Davis BR, Probstfield JL; ALLHAT Collaborative Research Group.

J Clin Hypertens (Greenwich). 2013 Nov;15(11):825-32. doi: 10.1111/jch.12180. Epub 2013 Aug 7.

24.
25.

The necessity for clinical reasoning in the era of evidence-based medicine.

Sniderman AD, LaChapelle KJ, Rachon NA, Furberg CD.

Mayo Clin Proc. 2013 Oct;88(10):1108-14. doi: 10.1016/j.mayocp.2013.07.012.

PMID:
24079680
26.

Ensuring the integrity of clinical practice guidelines: a tool for protecting patients.

Lenzer J, Hoffman JR, Furberg CD, Ioannidis JP; Guideline Panel Review Working Group.

BMJ. 2013 Sep 17;347:f5535. doi: 10.1136/bmj.f5535. No abstract available. Erratum in: BMJ. 2014;348:f1335.

PMID:
24046286
27.

Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study.

Yasar S, Xia J, Yao W, Furberg CD, Xue QL, Mercado CI, Fitzpatrick AL, Fried LP, Kawas CH, Sink KM, Williamson JD, DeKosky ST, Carlson MC; Ginkgo Evaluation of Memory (GEM) Study Investigators.

Neurology. 2013 Sep 3;81(10):896-903. doi: 10.1212/WNL.0b013e3182a35228. Epub 2013 Aug 2.

28.

Counterpoint: statins do reduce fatal events.

Sniderman AD, Thanassoulis G, Couture P, Williams K, Alam A, Furberg CD.

J Clin Lipidol. 2013 May-Jun;7(3):225-7; discussion 228. doi: 10.1016/j.jacl.2012.12.004. Epub 2013 Feb 8. No abstract available.

PMID:
23725923
29.

Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels.

Sealey JE, Alderman MH, Furberg CD, Laragh JH.

Am J Hypertens. 2013 Jun;26(6):727-38. doi: 10.1093/ajh/hpt034. Epub 2013 Apr 2. Review.

PMID:
23548411
30.

Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.

Oparil S, Davis BR, Cushman WC, Ford CE, Furberg CD, Habib GB, Haywood LJ, Margolis K, Probstfield JL, Whelton PK, Wright JT Jr; ALLHAT Collaborative Research Group.

Hypertension. 2013 May;61(5):977-86. doi: 10.1161/HYPERTENSIONAHA.111.00213. Epub 2013 Mar 25.

31.

Expedited review of new drugs--reply.

Moore TJ, Furberg CD.

JAMA. 2013 Jan 16;309(3):237. doi: 10.1001/jama.2012.56920. No abstract available.

PMID:
23321757
32.

Cardiovascular disease risk prediction factors.

Sniderman AD, Furberg CD.

JAMA. 2012 Nov 21;308(19):1969; author reply 1970-1. doi: 10.1001/jama.2012.14049. No abstract available.

PMID:
23168814
33.

Call for worldwide withdrawal of tiotropium Respimat mist inhaler.

Beasley R, Singh S, Loke YK, Enright P, Furberg CD.

BMJ. 2012 Nov 9;345:e7390. doi: 10.1136/bmj.e7390. No abstract available.

PMID:
23144209
34.

How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?

Proschan M, Ford CE, Cutler JA, Graumlich JF, Pavlik V, Cushman WC, Davis BR, Alderman MH, Gordon D, Furberg CD, Franklin SS, Blumenthal SS, Castaldo RS, Preston RA; LHAT Collaborative Research Group.

Stat Med. 2013 Feb 28;32(5):884-97. doi: 10.1002/sim.5580. Epub 2012 Sep 7.

PMID:
22961832
35.

The safety risks of innovation: the FDA's Expedited Drug Development Pathway.

Moore TJ, Furberg CD.

JAMA. 2012 Sep 5;308(9):869-70. doi: 10.1001/jama.2012.9658. No abstract available.

PMID:
22948694
36.

Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies.

Madigan D, Sigelman DW, Mayer JW, Furberg CD, Avorn J.

Am Heart J. 2012 Aug;164(2):186-93. doi: 10.1016/j.ahj.2012.05.002. Epub 2012 Jul 3.

PMID:
22877803
37.

Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering.

Sniderman A, Thanassoulis G, Couture P, Williams K, Alam A, Furberg CD.

J Clin Lipidol. 2012 Jul-Aug;6(4):303-9. doi: 10.1016/j.jacl.2012.05.004. Epub 2012 May 30.

PMID:
22836065
38.

Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications.

Singh S, Loke YK, Enright P, Furberg CD.

Thorax. 2013 Jan;68(1):114-6. doi: 10.1136/thoraxjnl-2011-201275. Epub 2012 Jul 4. Review.

PMID:
22764216
39.

Comparison of coronary calcium screening versus broad statin therapy for patients at intermediate cardiovascular risk.

Sniderman AD, Thanassoulis G, Lawler PR, Williams K, Furberg CD.

Am J Cardiol. 2012 Aug 15;110(4):530-3. doi: 10.1016/j.amjcard.2012.04.025. Epub 2012 May 10.

PMID:
22579082
40.

Pluralism of viewpoints as the antidote to intellectual conflict of interest in guidelines.

Sniderman AD, Furberg CD.

J Clin Epidemiol. 2012 Jul;65(7):705-7. doi: 10.1016/j.jclinepi.2012.01.009. Epub 2012 Apr 26. No abstract available.

PMID:
22542359
41.

Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.

Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.

Hypertension. 2012 May;59(5):926-33. doi: 10.1161/HYPERTENSIONAHA.111.180554. Epub 2012 Mar 19.

42.

Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study.

Nelson TL, Biggs ML, Kizer JR, Cushman M, Hokanson JE, Furberg CD, Mukamal KJ.

J Clin Endocrinol Metab. 2012 May;97(5):1695-701. doi: 10.1210/jc.2011-3026. Epub 2012 Mar 7.

43.

Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study.

Brancati FL, Evans M, Furberg CD, Geller N, Haffner S, Kahn SE, Kaufmann PG, Lewis CE, Nathan DM, Pitt B, Safford MM; Look AHEAD Study Group.

Clin Trials. 2012 Feb;9(1):113-24. doi: 10.1177/1740774511432726.

44.

The FDA and new safety warnings.

Moore TJ, Singh S, Furberg CD.

Arch Intern Med. 2012 Jan 9;172(1):78-80. doi: 10.1001/archinternmed.2011.618. No abstract available.

PMID:
22232155
45.

Approaches to data analyses of clinical trials.

Furberg CD, Friedman LM.

Prog Cardiovasc Dis. 2012 Jan-Feb;54(4):330-4. doi: 10.1016/j.pcad.2011.07.002.

PMID:
22225999
46.

The causal exposure model of vascular disease.

Sniderman AD, Lawler PR, Williams K, Thanassoulis G, de Graaf J, Furberg CD.

Clin Sci (Lond). 2012 Apr;122(8):369-73. doi: 10.1042/CS20110449.

47.

Five years of Trials.

Altman DG, Hrynaszkiewicz I, Furberg CD, Grimshaw JM, Rothwell PM.

Trials. 2011 Nov 23;12:248. doi: 10.1186/1745-6215-12-248.

48.

Understanding drug safety and how to maximize it for patients.

Furberg CD.

JAAPA. 2011 Nov;24(11):16. No abstract available.

PMID:
22111175
49.

Suicidal behavior and depression in smoking cessation treatments.

Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S.

PLoS One. 2011;6(11):e27016. doi: 10.1371/journal.pone.0027016. Epub 2011 Nov 2.

50.

Public health policies: no place for surrogates.

Furberg CD.

Am J Hypertens. 2012 Jan;25(1):21. doi: 10.1038/ajh.2011.203. Epub 2011 Nov 9. No abstract available.

PMID:
22068711

Supplemental Content

Loading ...
Support Center